# Pazopanib, Lapatinib or Trastuzumab in Subjects With Solid Tumors

> **NCT01454804** · PHASE1 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 43 (actual)

## Conditions studied

- Advanced Cancers

## Interventions

- **DRUG:** Pazopanib
- **DRUG:** Lapatinib
- **DRUG:** Trastuzumab (Herceptin®)
- **DRUG:** Pazopanib

## Key facts

- **NCT ID:** NCT01454804
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-10
- **Primary completion:** 2015-03
- **Final completion:** 2015-03
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2016-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01454804

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01454804, "Pazopanib, Lapatinib or Trastuzumab in Subjects With Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01454804. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*